The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis
BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5785-z
Full Text
Open PDFAbstract
Available in full text
Date
June 10, 2019
Authors
Publisher
Springer Science and Business Media LLC